StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
BioMarin Pharma (BMRN) Updates on Vosoritide Phase 2 in Achondroplasia; Evidence of Durability Noted
April 20, 2016 10:40 AM
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) provided an update on its Phase 2 study of vosoritide, an analog of C-type Natriuretic ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Next Articles
BioMarin Pharma (BMRN) Announces Enrollment of First BMN 250 Phase 1/2 Patient for MPS IIIB
April 21, 2016 4:34 PM
BioMarin Provides Program Update on Vosoritide in Achondroplasia
April 20, 2016 10:36 AM
BioMarin Pharma (BMRN) Announces Positive Preclinical Data from BMN 270 Phase 1/2 in Hemophilia A
April 20, 2016 8:31 AM
BioMarin Provides Encouraging Preliminary Data on First 8 Patients in Hemophilia A Gene Therapy Program
April 20, 2016 8:30 AM
Form CT ORDER BIOMARIN PHARMACEUTICAL
April 18, 2016 1:24 PM
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) to Ring The Nasdaq Stock Market Closing Bell
April 18, 2016 10:21 AM
